Dan Skovronsky knows what makes good obesity drugs.
As a Chief Scientific Officer Eli LillyHe has already done it with the company's weekly shot, Zepbound. He tries to do with a more comfortable daily pill again and repeats the feat with a shot that could be even more powerful than Zepbound. And that doesn't count the other nine obesity medication Lilly's tests in clinical studies.
Skovronsky said that the race for the next big medication is no longer just about weight loss, but that more investors and analysts begin to say.
Take AmgenExperimental drug Maritide: In a study of the second phase, people lost up to 20% of their body weight and Amgen shares fell during the day when the results were released in November. Why? The investors feared that it would not be enough to compete with Lillys Zepbound and the Wegovy from Novo Nordisk, both of whom will have a long lead.
An Eli Lilly & Co. Zepbound Injection Stift, which was arranged on Thursday, March 28, 2024, in the municipality of Brooklyn in New York, USA.
Shelby Knowles | Bloomberg | Getty pictures
Skovornsky sees the improvement of user -friendliness and the production of stronger drugs than two ways to move the field forward. He represents pills like Lillys Orforlipron who reach people around the world. He sees medication that can deliver more weight loss – possibly also Lilly's own retatrutide – as another area with potential.
More CNBC health insurance
But he is most excited to see how many other health states that can be incorporated or treated with intestinal hormone. Lillys Zepbound was recently approved for the treatment of sleep apnea. The company also examines whether it can be treated Addiction, heart disease, inflammation and gastrointestinal diseases.
You can watch the full interview for more from Skovronsky about Lilly's work in obesity and the place where he sees the market.
Comments are closed.